M A Sandberg1, A Weiner, S Miller, A R Gaudio. 1. Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston 02114, USA.
Abstract
OBJECTIVE: This study aimed to determine whether clinical tests of ocular function and macular appearance independently can help to predict which patients with unilateral neovascular age-related macular degeneration (AMD) will have a choroidal neovascular membrane (CNVM) develop in their fellow eye. DESIGN: The study design was a prospective cohort study. PARTICIPANTS: One hundred twenty-seven patients with unilateral neovascular AMD observed for up to 4.5 years participated. INTERVENTION: Functional measurements included visual acuity, macular visual field, glare recovery time, and foveal electroretinogram amplitude and implicit time. MAIN OUTCOME MEASURE: The age-adjusted proportion of patients having a CNVM develop over follow-up assessed by the Cox proportional hazards model with stepwise selection was measured. RESULTS: On average, 8.8% of patients had a CNVM develop each year. Independent risk factors for the fellow eye were its glare recovery time in minutes (relative risk = 1.30, confidence interval = 1.10-1.54, P = 0.003) and its extent of visible macular abnormalities on a four-point scale (relative risk = 1.62, confidence interval = 1.06-2.59, P = 0.03). Of the fellow eyes that converted, the interval to have a CNVM develop was inversely related to the foveal electroretinogram implicit time. CONCLUSIONS: A slower recovery from glare and more extensive funduscopic changes appear to be independent risk factors for the development of a CNVM in the fellow eyes of patients with unilateral neovascular AMD. A slower foveal electroretinogram implicit time may be a sign of early stage CNVM development, perhaps because of outer retinal ischemia. These results have clinical management implications, particularly for those patients at high risk of having a potentially treatable form of AMD develop.
OBJECTIVE: This study aimed to determine whether clinical tests of ocular function and macular appearance independently can help to predict which patients with unilateral neovascular age-related macular degeneration (AMD) will have a choroidal neovascular membrane (CNVM) develop in their fellow eye. DESIGN: The study design was a prospective cohort study. PARTICIPANTS: One hundred twenty-seven patients with unilateral neovascular AMD observed for up to 4.5 years participated. INTERVENTION: Functional measurements included visual acuity, macular visual field, glare recovery time, and foveal electroretinogram amplitude and implicit time. MAIN OUTCOME MEASURE: The age-adjusted proportion of patients having a CNVM develop over follow-up assessed by the Cox proportional hazards model with stepwise selection was measured. RESULTS: On average, 8.8% of patients had a CNVM develop each year. Independent risk factors for the fellow eye were its glare recovery time in minutes (relative risk = 1.30, confidence interval = 1.10-1.54, P = 0.003) and its extent of visible macular abnormalities on a four-point scale (relative risk = 1.62, confidence interval = 1.06-2.59, P = 0.03). Of the fellow eyes that converted, the interval to have a CNVM develop was inversely related to the foveal electroretinogram implicit time. CONCLUSIONS: A slower recovery from glare and more extensive funduscopic changes appear to be independent risk factors for the development of a CNVM in the fellow eyes of patients with unilateral neovascular AMD. A slower foveal electroretinogram implicit time may be a sign of early stage CNVM development, perhaps because of outer retinal ischemia. These results have clinical management implications, particularly for those patients at high risk of having a potentially treatable form of AMD develop.
Authors: Stephen A Burns; Ann E Elsner; Mariane B Mellem-Kairala; Ruthanne B Simmons Journal: Invest Ophthalmol Vis Sci Date: 2003-09 Impact factor: 4.799
Authors: M Uyama; K Takahashi; N Ida; M Miyashiro; A Ando; A Takahashi; E Yamada; J Shirasu; Y Nagai; M Takeuchi Journal: Br J Ophthalmol Date: 2000-09 Impact factor: 4.638
Authors: J S Wolffsohn; S J Anderson; J Mitchell; A Woodcock; M Rubinstein; T Ffytche; A Browning; K Willbond; W M Amoaku; C Bradley Journal: Br J Ophthalmol Date: 2006-04 Impact factor: 4.638
Authors: Zhichao Wu; Robyn H Guymer; Chang J Jung; Jonathan K Goh; Lauren N Ayton; Chi D Luu; David J Lawson; Andrew Turpin; Allison M McKendrick Journal: Transl Vis Sci Technol Date: 2015-06-30 Impact factor: 3.283
Authors: Lori A Lott; Marilyn E Schneck; Gunilla Haegerstrom-Portnoy; Susan Hewlett; Natalie Stepien-Bernabe; Bonnie M Gauer; Ali Zaidi; Arthur D Fu; John A Brabyn Journal: Ophthalmic Epidemiol Date: 2020-08-12 Impact factor: 1.648
Authors: João Pedro Marques; Miguel Costa; Pedro Melo; Carlos Manta Oliveira; Isabel Pires; Maria Luz Cachulo; João Figueira; Rufino Silva Journal: ISRN Ophthalmol Date: 2013-07-30